Education
About Us
Working with TipRanks
Follow Us
Restart Life Sciences (NMLSF)
OTHER OTC:NMLSF
NMLSF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.10
Previous CloseN/A
Volume8.00K
Average Volume (3M)249.00
Market Cap
$1.83M
Enterprise Value$1.92M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)4.8
Beta2.93
Next Earnings
Nov 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding36,050,354
10 Day Avg. Volume58
30 Day Avg. Volume249
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Restart Life Sciences News
NMLSF FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was $0.02 and its highest was $0.10 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is $1.83M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Nov 26, 2025 which is in 67 days.
How were Restart Life Sciences’s earnings last quarter?
Restart Life Sciences released its earnings results on Aug 22, 2025. The company reported -$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.004.
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 36,050,354 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Restart Life Sciences reported an EPS of -$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 16.667%.
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in NMLSF
Company Description
Restart Life Sciences
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mind and body wellness for healthy living, as well as psilocybin clinical trial for fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---